The Journal of the Korean dental association (대한치과의사협회지)

The Korean Dental Association (대한치과의사협회)
권호 표지

Guidelines for Dental clinicians in case of medically compromised Patients: Case reports of medically compromised patients taking oral Bisphosphonate

전신질환자 구강외과 소수술시의 주의사항 -골다공증약 복용환자 수술 포함-

  • Kim, Sun-Jong (Department of Oral and Maxillofacial surgery, Mok-dong Hospital School of Medicine, Ewha Womans University) ;
  • Kim, Myung-Rae (Department of Oral and Maxillofacial surgery, Mok-dong Hospital School of Medicine, Ewha Womans University)
  • 김선종 (이화여자대학교 의학전문대학원 치과학교실 구강악안면외과) ;
  • 김명래 (이화여자대학교 의학전문대학원 치과학교실 구강악안면외과)
  • Published : 2010.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Dental surgical procedures are potentially stress-inducing to not only patients but clinicians especially in case of medically compromised patients. The body response to dental stress involves the cardiovascular, respiratory and the endocrine system. To minimize the stress to the medically compromised patients, the stress reduction protocols should be established. The protocols include (1) Recognize the patient's degree of medical risk (2) Medical consultation before dental therapy (3) Schedule the patient's appointment in the morning (4) Monitor and record preoperative, perioperative and postoperative vital signs (5) Intra-venous sedation during surgical procedures (6) Adequate pain control during therapy (7) Short length of appointment time (8) Contact the patients on the same day. Two cases of Bisphosphonate-related osteonecrosis of the jaws were analyzed. There were 2 women, and the mean age was 70 years (range, 64~74 years). both are medically compromised, with steroids. Both patients were taking an oral bisphosphonate for several years. BRONJ is defined as an area of exposed bone of more than 8 weeks - duration in a patient taking a bisphosphonate for bone disease. Bisphosphonates have been widely prescribed over the last decade for a range of bone diseases, mainly intravenously for bone cancers and orally for osteoporosis. Although it is still controversial as to precisely how the bisphosphonates work, generally it is accepted that they prevent osteoclast action, with consequent cessation of osteoblast activity, so that the bone turnover is markedly reduced or ceased. The aim of this study is to informed the clinicians how to prepare and recognize in case of the BRONJ with medically compromised patients.

Keywords

References

  1. Lapointe HJ, Armtrong JE, Laroque B. : A clinical criteria for the use of a decision-making framework for the medically compromised patient; hypertension and diabetes mellitus. J Can Dent Assoc. 1997: 704:63(7): 704
  2. Kilmartin CM. : Managing the medically compromised geriatric patient. J Prosthet Dent, 1994:72(5): 492. https://doi.org/10.1016/0022-3913(94)90121-X
  3. Lapointe HJ, Armtrong JE, Laroque B. : A clinical decision making framework for the medically compromised patient: ischemic heart disease and chronic obstructive pulmonary disease. J Can Dent Assoc, 1997:63(7): 510
  4. Umino M, Nagao M. : Systemic diseases in elderly dental patients. Int. Dent J. 1993:43(3): 213
  5. Meyerowitz C. : Geriatric dentistry and prevention: research and public policy. Adv Dent Periodontol, 1991: 5: 74.
  6. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  7. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76. https://doi.org/10.1016/j.joms.2006.11.003
  8. Khosla S, Burr D, Cauley J, et al. Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the americal society for bone and mineral research. J Bone Miner Res. 2007;22:1479 -91. https://doi.org/10.1359/jbmr.0707onj
  9. Choi et al Retrospective study on prognosis of the medically compromised patients in department of oral and Maxillofacial surgery.J Kor Acad Maxillifac Plast Reconstr Surg.2003:25(5);439-447
  10. Samuel J. McKenna. : Leukemia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2000: 89: 137 https://doi.org/10.1067/moe.2000.102386
  11. Sonksen et al. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth. 1999 Mar;82(3):360-5 https://doi.org/10.1093/bja/82.3.360
  12. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62: 527-34. https://doi.org/10.1016/j.joms.2004.02.004
  13. Marx RE: Pamdironate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61:1115, 2003 (letter) https://doi.org/10.1016/S0278-2391(03)00720-1
  14. MiglioratiCA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508-14. https://doi.org/10.1016/S1470-2045(06)70726-4
  15. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548-58. https://doi.org/10.1016/j.clinthera.2007.08.008
  16. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301. https://doi.org/10.1210/jc.2004-0952
  17. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American academy of oral medicine position paper. J Am Dent Assoc. 2005;136:1658-68.
  18. Lam DK, Sádor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73:417-22.
  19. Kasai et al. The Prognosis for Dental Implants Placed in Patients Taking Oral Bisphosphonates. CDA Journal, 2009: vol 37; no1;39-42
  20. Carter GD, Goss AN: Letter to the editor. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48:268, 2003
  21. Saif MW Management of Bisphosphonate-Related Osteonecrosis of the Jaw JOP. J Pancreas (Online) 2009 Sep 4; 10(5):581-582.
  22. Ruggiero SL Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ)Clin Cases Miner Bone Metab. 2007 Jan-Apr; 4(1): 37-42
  23. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67(Suppl 5):2-12.